Log in to search using one of your social media accounts:

 

Mylan Says Allergan Misusing Tribal Sovereignty in Patent Dispute Mylan Says Allergan Misusing Tribal Sovereignty in Patent Dispute
Generic drugmaker Mylan NV alleged in a court filing that rival Allergan Plc is trying to take advantage of Native American sovereignty to shield its patent for the blockbuster dry-eye treatment Restasis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Mylan says Allergan misusing tribal sovereignty in patent dispute
NEW YORK (Reuters) - Generic drugmaker Mylan NV alleged in a court filing that rival Allergan Plc is trying to take advantage of Native American sovereignty to shield its patent for the blockbuster dry-eye treatment Restasis. (Source: Reuters: Health)
Source: Reuters: Health - September 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Allergan pays Mohawk Tribe to protect patents from challenges
(Reuters) - Allergan Plc will transfer to the Saint Regis Mohawk Tribe rights to its blockbuster Restasis dry-eye treatment, the drugmaker said on Friday, in an unusual deal to protect it from patent challenges. (Source: Reuters: Health)
Source: Reuters: Health - September 8, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Shire applies for European approval of potential blockbuster eye drop
One of the state ’s biggest biotech employers, Shire plc, has applied for European approval for its potential blockbuster eye drop to treat dry eye disease, sold by the name of Xiidra in the U.S. The drug, a twice-a-day eye drop that goes by the generic name of lifitegrast, was approved in the U.S. in August 2016 . It’s touted as the “first and only” drug in the world to treat the signs and symptoms of dry eye disease, and competes head-to-head with Restasis, a similarly-priced drug sold by… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 15, 2017 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news

Gengraf Capsules (Cyclosporine Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 11, 2017 Category: Drugs & Pharmacology Source Type: news

Allergan, Argentum settle patent dispute over eye drug Restasis
(Reuters) - U.S. generic drug company Argentum Pharmaceuticals LLC said on Tuesday it had reached an agreement with Allergan Plc that settles a patent dispute over the generic version of Allergan's eye drug, Restasis. (Source: Reuters: Health)
Source: Reuters: Health - April 18, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Allergan Announces Availability of RESTASIS MULTIDOSE(TM) (Cyclosporine Ophthalmic Emulsion) 0.05% -- the First FDA-Approved Preservative Free Prescription Eye Drop Available in a Multidose Bottle
DUBLIN, March 22, 2017 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN) today announced the availability of RESTASIS MULTIDOSE™, which is the same preservative-free RESTASIS® formulation, but now offered in a multidose bottle. RESTASIS&... Biopharmaceuticals, Ophthalmology, Product Launch Allergan, RESTASIS, Cyclosporine, Chronic Dry Eye (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 22, 2017 Category: Pharmaceuticals Source Type: news

Disseminated Nocardia farcinica Infection in a Patient with Steroid-dependent Autoimmune Hemolytic Anemia: Case Report and Literature Review
We describe a 64-year-old female with autoimmune hemolytic anemia (AIHA) who was steroid dependent and on cyclosporine immunosuppressive therapy. Nocardia farcinica was recovered from the patient's bronchoalveolar lavage (BAL) specimen and several blood cultures. (Source: Clinical Microbiology Newsletter)
Source: Clinical Microbiology Newsletter - January 20, 2017 Category: Microbiology Authors: Zeti Norfidiyati Ayub, Habsah Hasan, Mohd Zulfakar Mazlan, Alwi Muhd Besari Tags: Case Report Source Type: news

Similar Long-Term Ulcerative Colitis Outcomes With Cyclosporine or Infliximab Similar Long-Term Ulcerative Colitis Outcomes With Cyclosporine or Infliximab
Long-term outcomes of patients with steroid-refractory acute severe ulcerative colitis (UC) are similar whether treated with cyclosporine or infliximab, researchers from France report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 18, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Mylan, Allergan launch fight over Restasis eye drop patents
Allergan (NYSE:AGN) said this week that it will “vigorously defend” the patents for its Restasis eye drops, after the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board agreed to an inter partes review of 6 patents as requested by generic competitor Mylan (NSDQ:MYL). The patents are valid until August 2024. “Allergan is disappointed in the PTAB’s decision to institute IPR proceedings regarding the patents that protect Restasis,” the company wrote in a statement yesterday. “Allergan is currently reviewing the grounds for the decision to institute, and will continu...
Source: Mass Device - December 9, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Legal News Optical/Ophthalmic Pharmaceuticals Wall Street Beat Allergan Inc. Mylan Source Type: news

Gengraf Oral Solution (Cyclosporine Oral Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 22, 2016 Category: Drugs & Pharmacology Source Type: news

Neoral (Cyclosporine) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 22, 2016 Category: Drugs & Pharmacology Source Type: news

Allergan asks FDA to approve Oculeve neurostim device
Allergan (NYSE:AGN) said today that it filed a de novo approval application with the FDA for its Oculeve nasal neurostimulation device for dry eye it bought last year. Oculeve is a hand-held device designed to be inserted into the nostril to stimulate the nerves serving the lacrimal gland. Allergan paid $125 million plus unspecified milestones for Oculeve last year. The de novo protocol is for low- to moderate-risk devices that don’t have a “substantially equivalent predecessor” device already on the market. “The Oculeve intranasal tear neurostimulator is an exciting potential option ...
Source: Mass Device - July 18, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Neuromodulation/Neurostimulation Optical/Ophthalmic Regulatory/Compliance Allergan Inc. Oculeve Source Type: news

Cyclosporine of No Benefit in Cardiac Arrest (CME/CE)
(MedPage Today) -- Drug failed to improve outcomes in nonshockable patients (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 15, 2016 Category: Cardiology Source Type: news

Disheartening result for cyclosporine A in nonshockable cardiac arrest
Administering cyclosporine A at the time of resuscitation of patients with nonshockable out-of-hospital cardiac arrest does not reduce the likelihood of subsequent multiple organ failure, shows the results of the CYRUS trial. (Source: MedWire News)
Source: MedWire News - July 15, 2016 Category: Consumer Health News Tags: Cardiology Source Type: news

Persian Gulf War Veterans Still Suffering Serious Health Problems
This year marks the 25th anniversary of the Persian Gulf War. It was fought in late 1990 through early 1991 by a U.S.-led coalition of 34 countries against Iraq in response to Saddam Hussein's invasion of Kuwait. It also was the first U.S. war to be waged after the advent of the 24-hour cable television news cycle. The conflict was accompanied by memorably intense and round-the-clock coverage on CNN. But there've been few recognitions of the war's 25-year milestone on the cable news networks, let alone in broadcast or print media. For David Winnett, a Gulf War combat veteran who climbed the ranks from private to capta...
Source: Healthy Living - The Huffington Post - June 21, 2016 Category: Consumer Health News Source Type: news

Three decades beat as one: 30 years of heart transplants
Tina Medina and her son Luke Tina Medina was not a sickly child, yet she grew up knowing something was physically wrong. She had difficulty keeping up with the other kids in her sixth-grade class and couldn’t run without becoming breathless. Local physicians near her home in Moriah, New York, shrugged it off as asthma — until Tina’s heart stopped twice during a routine appendectomy. “I was told I had a severe heart condition and needed to see a cardiologist right away,” she says. At 15, Tina was diagnosed with restrictive cardiomyopathy, a rare type of cardiomyopathy that causes the heart...
Source: Thrive, Children's Hospital Boston - June 13, 2016 Category: Pediatrics Authors: Emily Williams Tags: Diseases & Conditions Our Patients’ Stories Research and Innovation cardiac surgery cardiomyopathy congential heart defect Department of Cardiac Surgery Dr. Elizabeth Blume Dr. John Mayer ECMO Heart Center heart transplant Heart Source Type: news

Allergan’s Oculeve on track for FDA submission this year
Allergan (NYSE:AGN) said today that it’s on track for an FDA submission this year for the Oculeve nasal neurostimulation device for dry eye it bought last year. Oculeve is a hand-held device designed to be inserted into the nostril to stimulate the nerves serving the lacrimal gland. Allergan paid $125 million plus unspecified milestones for Oculeve last year. Today the company said a pair of pivotal trials passed their safety and efficacy endpoints, clearing the way for a pre-market approval submission in the 2nd half of the year. The 48-patient OCUN-009 trial evaluated intra- and e...
Source: Mass Device - May 16, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Clinical Trials Food & Drug Administration (FDA) Optical/Ophthalmic Regulatory/Compliance Allergan Inc. Oculeve Source Type: news

Cyclosporine Capsules (New - Discontinuation)
Updated Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - May 11, 2016 Category: Drugs & Pharmacology Source Type: news

Allergan Receives Complete Response Letter from FDA for Prior Approval Supplement for RESTASIS(R) (Cyclosporine Ophthalmic Emulsion) 0.05% Multi-Dose Preservative-Free Bottle
DUBLIN, March 10, 2016 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN) announced today it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its Prior Approval Supplement (PAS) for RESTASIS® (C... Biopharmaceuticals, Ophthalmology, FDAAllergan, RESTASIS, Cyclosporine, Chronic Dry Eye (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 10, 2016 Category: Pharmaceuticals Source Type: news

Infliximab May Top Cyclosporine for Steroid-Refractory Ulcerative ColitisInfliximab May Top Cyclosporine for Steroid-Refractory Ulcerative Colitis
Infliximab may be slightly better than cyclosporine for treating patients with steroid-refractory ulcerative colitis (UC), according to results from a systematic review and meta-analysis. Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 1, 2016 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Nulojix Ups Survival in Kidney Transplant Patient (CME/CE)
(MedPage Today) -- Long-term risk of death, graft loss lower than with cyclosporine (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - January 27, 2016 Category: Surgery Source Type: news

Cyclosporine A Flops for PCI Cardioprotection (CME/CE)
(MedPage Today) -- Pharmacological post-conditioning suffers a blow (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 25, 2016 Category: Cardiology Source Type: news

HIV-1 Capsid Stabilization Assay
The stability of the HIV-1 core in the cytoplasm is crucial for productive HIV-1 infection. Mutations that stabilize or destabilize the core showed defects in HIV-1 reverse transcription and infection. We developed a novel and simple assay to measure stability of in vitro-assembled HIV-1 CA-NC complexes. This assay allowed us to demonstrate that cytosolic extracts strongly stabilize the HIV-1 core (Fricke et al., J Virol 87:10587–10597, 2013). By using our novel assay, one can measure the ability of different drugs to modulate the stability of in vitro-assembled HIV-1 CA-NC complexes, such as PF74, CAP-1, IXN-053, cy...
Source: Springer protocols feed by Immunology - December 7, 2015 Category: Allergy & Immunology Source Type: news

Scientists identify potential birth control 'pill' for men
Two drugs that help suppress the immune system in organ transplant patients may have a future as the long-sought birth control "pill" for men, new research suggests. The drugs – cyclosporine A (also known as CsA) and FK506 (also known as tacrolimus) – are given to transplant recipients to reduce... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - October 1, 2015 Category: Science Authors: Karen Kaplan Source Type: news

The Cardiology Show From ESC 2015 with Dr Valentin FusterThe Cardiology Show From ESC 2015 with Dr Valentin Fuster
The panel discuss a leadless pacemaker, cyclosporine and reperfusion injury, hypertension treatments, high-sensitivity troponin for early MI diagnosis, and yet more data on antithrombins for PCI. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 2, 2015 Category: Cardiology Tags: Cardiology Roundtable Source Type: news

News from the European Society of Cardiology Conference (FREE)
By the Editors Here's a quick look at some of the major news that came out of the European Society of Cardiology Congress in London this weekend:Cyclosporine Before Percutaneous Coronary Intervention? Among patients with acute anterior … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 31, 2015 Category: Primary Care Source Type: news

CIRCUS: No Cyclosporine Benefit in STEMI PCI Setting CIRCUS: No Cyclosporine Benefit in STEMI PCI Setting
Hopeful that cyclosporine could limit myocardial reperfusion injury, as shown in small studies and animal models, CIRCUS investigators failed to show an improvement in hard clinical outcomes following PCI for STEMI. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 30, 2015 Category: Cardiology Tags: Cardiology News Source Type: news

ESC: Cyclosporine Fails to Prevent Reperfusion Injury
(MedPage Today) -- No reduction in left ventricular remodeling, according to CIRCUS study results (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - August 30, 2015 Category: Journals (General) Source Type: news

Cyclosporine does not improve outcomes after PCI
(European Society of Cardiology) The immunosuppressant drug cyclosporine did not improve clinical outcomes compared to placebo in patients receiving percutaneous coronary intervention for the more severe form of heart attack known as ST-segment elevation myocardial infarction. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 30, 2015 Category: Global & Universal Source Type: news

Pharmaceutics and Drug Delivery - 2002
Guest Editor(s) Bruce Aungst Introduction Pharmaceutics and drug delivery Author(s) Bruce Aungst Role of plasma lipoproteins in modifying the toxic effects of water insoluble drugs Studies with cyclosporine A Author(s) Kishor M. Wasan Manisha Ramaswamy Mona Kwong Kathy D. (Source: AAPS Publications)
Source: AAPS Publications - August 19, 2015 Category: Drugs & Pharmacology Source Type: news

Allergan closes $125m Oculeve buy
Allergan said yesterday it closed its purchase of dry eye disease device developer Oculeve for $125 million in up-front payments in addition to unspecified commercialization milestones. South San Francisco-based Oculeve is developing a product called OD-01, a non-invasive nasal neurostimulation device designed to increase tear production in patients with dry eye disease, Allergan said. Oculeve has completed 4 clinical trials of OD-01 to date. “The acquisition of Oculeve further enhances Allergan’s world-class position in eye care and underscores our commitment to continuing to develop a broad range of...
Source: Mass Device - August 11, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Mergers & Acquisitions Optical/Ophthalmic Allergan Inc. Oculeve Source Type: news

WCD: Methotrexate found safer but less effective than cyclosporine in atopic dermatitis
VANCOUVER, B.C. – In the first head-to-head trial in atopic dermatitis, cyclosporine was about five times more effective in terms of SCORAD 50 but was associated with more adverse events, Dr. Catherine Goujon-Henry reported at the World Congress of Dermatology. Based on the findings,...googletag.display('div-gpt-ad-cta'); (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 27, 2015 Category: Dermatology Tags: SAN Conference News IMN Conferences SAN Atopic Dermatitis SAN Clinical News SAN News IMN News IMN Dermatology Source Type: news

Topical Cyclosporine Better for Ocular RosaceaTopical Cyclosporine Better for Ocular Rosacea
A new comparative study has found that topical cyclosporine is more effective than oral doxycycline at relieving symptoms and treating eyelid and dry eye signs in patients with ocular rosacea. Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - June 27, 2015 Category: Dermatology Tags: Ophthalmology News Source Type: news

There's Relief In Sight For People With Perpetually Dry Eyes
By Janice Neumann (Reuters Health) - Tiny plugs inserted into the tear duct may safely curb the annoying and damaging effects of dry eyes, according to a new analysis of previous research. "Plugs are generally well tolerated," said Dr. Marcus Marcet, an ophthalmologist at the University of Hong Kong and the study's first author. "Overall the extent of relief depends on both the type of dry eye and the type of plug." Patients with dry eyes who might benefit from plugs are those who have already tried eye drops and gels but still have itchy, red, painful eyes, blurred vision and the sensation of a foreign...
Source: Science - The Huffington Post - June 23, 2015 Category: Science Source Type: news

Consider combining therapies for atopic dermatitis
Cyclosporine and oral antihistamine therapy showed inconsistent effects on clinical and laboratory markers of atopic dermatitis in older children and adults, based on data from a study of 48 patients. A total of 25 patients aged 16-42 years received oral cyclosporine and 23 patients aged 15-32...googletag.display('div-gpt-ad-cta'); (Source: Skin and Allergy News)
Source: Skin and Allergy News - June 9, 2015 Category: Dermatology Tags: IMN News IMN Dermatology FPN News FPN Dermatology SAN Clinical News SAN News SAN Atopic Dermatitis Source Type: news

3-D printed, mechanically robust carrier used to deliver immunosuppressive drug, and cells
(Cell Transplantation Center of Excellence for Aging and Brain Repair) After a 3-D printer was used to create a micro but mechanically robust drug and cell carrier for local and sustained delivery of the immunosuppressive drug cyclosporine, researchers demonstrated in tests with animal models that the carrier, a combination of microspheres and hydrogel, maintained robust shape and integrity and delivered a local, sustained release of CsA in an amount that prevented acceleration of cytokines and overcame the need for additional drugs to treat immune rejection. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 23, 2015 Category: Global & Universal Source Type: news

The Hearts Of Mary Shelley
"Perhaps a corpse would be reanimated... perhaps the components parts of a creature might be manufactured, brought together and endued with vital warmth." -Mary Shelley On Valentine's Day, we consider the heart. The heart is biological; it is the organ on which our life most depends. The heart is emotional, full of love and sorrow. The heart is wandering. No one knew our central muscle's multiple meanings better than Mary Shelley. Mary Shelley was a writer's writer, depressive, miserable, and brilliant. So too the friends she gathered with, at the age of 18, in the spring of 1816 at two adjacent houses on L...
Source: Science - The Huffington Post - February 11, 2015 Category: Science Source Type: news

Celgene’s Otezla® (apremilast) receives European marketing authorisation
Celgene UK announced that the European Commission has licenced Otezla®, the company’s oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic indications: (2) For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA). Alone or in combination with disease-modifying antirheumatic drugs (DMARDs), for the treatment of active psoriatic arthritis in adult patients who have had an inadequat...
Source: Pharmacy Europe - January 16, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Legislation & regulation Dermatology Rheumatology Patient care chronic plaque psoriasis DMARD Latest News PDE4 inhibitor psoriatic arthritis PUVA Source Type: news

Dollars for Dudes: Almost no women among medical industry's top-paid speakers, consultants
The causes are not clear, but men account for more than 90 percent of the 300 doctors who received the most money from drug and medical device companies, according to new federal data. Alison Tendler, an ophthalmologist who works in Sioux Falls, S.D., is among the few women on a list of the doctors paid the most money by drug companies last year. That's primarily because she serves as the TV advertising spokeswoman for the eye drug Restasis. Centers for Medicare and Medicaid Services (CMS), ProPublicaNews Well, Medicareread more (Source: Mass Device)
Source: Mass Device - October 8, 2014 Category: Medical Equipment Authors: MassDevice Source Type: news

How Does Pediatric Psoriasis Present?
Discussion Psoriasis is an inflammatory skin disease that is chronic and relapsing with periods of remission. It occurs in genetically susceptible persons and is felt to be triggered by environmental factors including infection (especially Group A, β-hemolytic streptococcus), emotional and physical stress, and skin irritation including friction, rubbing, pressure and scratching. It is common in patients with certain HLA types including HLA-Cw*0602, HLA-Cw6, IL-15 plus others. It occurs in about 1% of the general population with two age-onset peaks: 16-22 years and ~60 years, but can occur at any age. Some studies show...
Source: PediatricEducation.org - April 14, 2014 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Roche launches new tests for monitoring transplant patients on immunosuppressive therapy
Roche today announced the global launch (except US) of two new highly sensitive therapeutic drug monitoring tests for the immunosuppressant medicines tacrolimus and cyclosporine. The new Elecsys Tacrolimus and Cyclosporine tests provide healthcare professionals with more accurate and reliable results. They are made for use on Roche’s cobas modular analysers, thus also supporting enhanced workflow and efficiency in medical laboratories. (Source: Roche Investor Update)
Source: Roche Investor Update - July 19, 2013 Category: Pharmaceuticals Source Type: news

Roche launches new tests for monitoring transplant patients on immunosuppressive therapy
Roche today announced the global launch (except US) of two new highly sensitive therapeutic drug monitoring tests for the immunosuppressant medicines tacrolimus and cyclosporine. The new Elecsys Tacrolimus and Cyclosporine tests provide healthcare professionals with more accurate and reliable results. They are made for use on Roche’s cobas modular analysers, thus also supporting enhanced workflow and efficiency in medical laboratories. (Source: Roche Media News)
Source: Roche Media News - July 19, 2013 Category: Pharmaceuticals Source Type: news

Everolimus vs Mycophenolate Mofetil in Heart TransplantationEverolimus vs Mycophenolate Mofetil in Heart Transplantation
In an open-label, 24-month trial, 721 de novo heart transplant recipients were randomized to everolimus 1.5 mg or 3.0 mg with reduced-dose cyclosporine, or mycophenolate mofetil 3 g/day with standard-dose cyclosporine. American Journal of Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 12, 2013 Category: Consumer Health News Tags: Transplantation Journal Article Source Type: news

Cyclosporine May Be an Option in Allergic ConjunctivitisCyclosporine May Be an Option in Allergic Conjunctivitis
Topical cyclosporine may spare patients the adverse effects associated with corticosteroids, investigators say. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 9, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Infliximab Better Than Cyclosporine in Refractory ColitisInfliximab Better Than Cyclosporine in Refractory Colitis
Infliximab appears to be better than cyclosporine as salvage therapy for steroid-refractory acute severe ulcerative colitis (UC), researchers from Australia report. Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2013 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

New Automated Immunosuppressive Drug Assays Improve Therapeutic Drug Monitoring for Transplant Patients
For the first time, certain immunosuppressive drug (ISD) assays can now be performed automatically on cobas® modular platforms, allowing laboratories to consolidate testing for a wide range of transplant testing/monitoring assays onto a single platform. The new Roche automated assays for tacrolimus and cyclosporine will enhance therapeutic drug monitoring (TDM) of transplant recipients by providing the consistency and accuracy of an automated assay, while enhancing workflows, auditing and reporting capabilities in the laboratory. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - July 2, 2013 Category: Pharmaceuticals Source Type: news

600th Heart Attack Patient Recruited Into Phase III CicloMulsion® CIRCUS Trial
NeuroVive, a leading mitochondrial medicine company, announces that the 600th patient has been recruited to a pivotal Phase III European, multi-center trial (CIRCUS trial) assessing CicloMulsion® (a special formulation of cyclosporine for acute cardiac injuries) for the treatment of heart reperfusion injury following stenting in patients with myocardial infarction... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 27, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news

Abuse of Opana ER (oxymorphone) associated with thrombotic thrombocytopenic purpura
3.5 out of 5 stars Thrombotic Thrombocytopenic Purpura (TTP)-Like Illness Associated with Intravenous Opana ER Abuse — Tennessee, 2012. MMWR 2013 Jan 11;62:1-4. Full Text This paper describes a 2012  CDC investigation into a cluster of 15 cases of thrombotic thrombocytopenic purpura (TTP)-like illness in the state of Tennessee. TTP-like illness was defined as microangiopathic hemolytic anemia (hemolytic anemia anemia based on haptoglobin and lactate dehydrogenase with schistocytes and an admission platelet count 
Source: The Poison Review - January 15, 2013 Category: Toxicology Authors: Leon Tags: Medical opana oxymorphone thrombotic thrombocytopenic purpura ttp Source Type: news